Hypercalcemia may develop both spontaneously and as a result of androgen therapy in women with disseminated breast carcinoma. If it develops while on this agent, the drug should be discontinued. Caution is required in administering these agents to patients with cardiac, renal or hepatic disease. Cholestatic jaundice is associated with therapeutic use of anabolic and androgenic steroids. Edema may occur occasionally with or without congestive heart failure. Concomitant administration of adrenal steroids or ACTH may add to the edema. In children, anabolic steroid treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months. This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.
All anabolic steroids have a tendency to reduce HDL (good) cholesterol and increase LDL (bad) cholesterol. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable) type of steroid (aromatizable or non-aromatizable) and level of resistance to hepatic metabolism. With regards to nandrolone at a dose of 600mg per week over 10 weeks demonstrated 26% reduction in HDL cholesterol levels. This suppression is slightly greater than an equal dose of testosterone over an equal period. In other words it shows a slightly more negative impact on HDL/LDL ratio with nandrolone than with testosterone cypionate. It’s always recommended to accompany the use of this product with a low saturated fat diet and a cardiovascular exercise program.